For adults with cystic fibrosis (CF), long-term treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) may significantly improve the composition of bacteria living in the lungs, a study found. The study showed that with longer periods of Trikafta treatment, the community of lung bacteria (respiratory microbiota) became more diverse. Disease-causing (pathogenic) bacteria…